The Effect of Bevacizumab on Corneal Neovascularization in Rabbits by Kim, Wung-Jae et al.
230
Korean J Ophthalmol 2010;24(4):230-236
DOI: 10.3341/kjo.2010.24.4.230 pISSN: 1011-8942 eISSN: 2092-9382
Original Article
The Effect of Bevacizumab on Corneal 
Neovascularization in Rabbits
Wung-Jae Kim, Hee-Ok Jeong, Sung-Kun Chung
Department of Ophthalmology, St. Mary’s Hospital, The Catholic University of Korea School of Medicine, Seoul, Korea
Purpose: To determine the efficacy of topical application and subconjunctival injection of bevacizumab in the treat-
ment of corneal neovascularization. 
Methods: Corneal neovascularization was induced with a silk suture of the corneal stroma in 12 rabbits (24 
eyes). One week after suturing, four rabbits were treated with topical bevacizumab at 5 mg/mL (group A) and an-
other four rabbits were treated with topical bevacizumab 10 mg/mL (group B) in the right eyes twice a day for two 
weeks.  A subconjunctival injection of bevacizumab 1.25 mg/mL was done in the right eyes of four rabbits (group C). 
All of the left eyes (12 eyes) were used as controls. The area of corneal neovascularization was measured after 
one and two weeks, and the concentration of vascular endothelial growth factor (VEGF) in corneal tissue was 
measured after two weeks.
Results: The neovascularized area was smaller in all treated groups than in the control group (p<0.001). Upon anal-
ysis of the neovascularized area, there was no significant difference between groups A and B. However, the 
mean neovascularized area of group B was significantly smaller than that of group C after two weeks of treatment 
(p=0.043). The histologic examination revealed fewer new corneal vessels in all treated groups than the control 
group. The concentration of VEGF was significantly lower in all treated groups compared to the control group 
(p<0.01), but no difference was shown between treated groups. 
Conclusions:  Topical and subconjunctival bevacizumab application may be useful in the treatment of corneal neo-
vascularization and further study is necessary. 
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Corneal neovascularization is a change of the final result 
of infectious, inflammatory, traumatic, and metabolic dis-
eases in the cornea, and approximately 4% of ophthalmic 
patients have this disease [1,2]. Occasionally, corneal neo-
vascularization is helpful to wound healing or the impedi-
ment of infection, however it reduces corneal transparency, 
and thus becomes the cause of visual acuity deterioration 
and it may become the cause of rejection reaction during 
corneal transplantation
 in most cases [2]. To treat and prevent 
corneal neovascularization, various medical therapies, pho-
todynamic therapy, and laser therapy have been attempted 
[3-11], but clinically established therapeutic procedures are 
not available.
Vascular endothelial growth factor (VEGF) has been reported 
to play a very important role in corneal neovascularization. It 
has been reported that upon VEGF polymer injection into rat 
cornea, the formation of neovascularization progressed very 
rapidly [12], and a higher concentration of VEGF and its re-
ceptor was detected than in normal cornea upon examination 
of human cornea neovascularization [13,14].
Bevacizumab (Avastin; Genentech, San Francisco, CA, 
USA) is a monoclonal antibody to the VEGF molecule, has 
been approved by the FDA for the treatment of colorectal 
cancer, and has been used actively in clinics [15]. In the oph-
thalmic field, by systemic injection or injection to the vitre-
ous cavity, it has been used effectively for the treatment of 
age-related macular degeneration as well as diabetic retinal 
edema or clinically significant macular edema and the results 
on such treatments have been reported [16-18]. In recent 
years, bevacizumab has been used to study corneal, con-
junctival, and retinal neovascularization with rabbits [19,20].HO Jeong, et al. Bevacizumab and Corneal Neovascularization
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Fig. 1. Microscopic examination of the neovascularized area in the cornea. (A,B,C) Control group. (D,E,F) Group treated with topical 5 
mg/mL bevacizumab. (G,H,I) Group treated with topical 10 mg/mL bevacizumab. (J,K,L) Group treated with subconjunctival bevacizumab 
1.25 mg injection. (A,D,G,J) Initial neovascularization of the cornea was observed. One week later, neovascularized areas were quite similar 
in the control group (B), but markedly regressed in the treated groups (E,H,K). After two weeks, neovascularized areas were somewhat re-
gressed in the control group (C), but significantly lower than that of treated groups (F,I,L).
   In this study, it was examined whether bevacizumab, 
which has been used actively in retinal applications, is effec-
tive on the corneal neovascularization treatment through a 
simple and safe route, via topical or subconjunctival in-
jection, in rabbit experiments. 
Materials and Methods
Experiment animals
This study was approved by the Institutional Animal Care 
and Use Committee of Korea, prior to experiments, and all 
the in vivo experiment procedures were performed according 
to regulation of Association for Research in Vision and 
Ophthalmology for the ophthalmic field and studies on visual 
function. Twelve New Zealand white rabbits (Samtako, 
Osan, Korea), weighing between 2.0 kg and 2.5 kg were used 
regardless of their sex; all rabbits were examined prior to sur-
gery and confirmed to have normal cornea. 
Induction of corneal neovascularization 
Systemic anesthesia was induced by the intramuscular in-
jection of the mixture of tilemine and zolazepam, Zoletil
 Korean J Ophthalmol Vol.24, No.4, 2010
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Fig. 2. Mean area of new vessels in the treated and control groups, 
and p-value between topically treated groups and group with sub-
conjunctival injection by Mann-Whitney U-test. The group treated 
with 10 mg/mL bevacizumab eye drops showed a more significant 
reduction of neovascularization area than the group treated by sub-
conjunctival injection at the second week. 
(Vibrac, Carros, France), at a 0.2 mg/kg dose, and topical an-
esthesia was induced by proparacaine eye drop (Alcaine; 
Alcon, Fort Worth, TX, USA). In 12 house rabbits  (24 eyes), 
a corneal suture 3 mm in length passing through the corneal 
stroma area was performed using 7-0 black silk (Sofsilk; 
Syneture, Quebec, Canada), at the 12 o’clock direction dis-
tanced from the corneal limbus by 1 mm. After suturing, to 
prevent infection, ofloxacin eye drops (Ocuflox; Samil, 
Seoul, Korea) were administered four times per day for seven 
days. One week later, the suture was removed after confirm-
ing the sufficient formation of corneal neovascularization.
Treatment of the neovascularization with bevacizumab 
To prevent error caused by the result of systemic absorp-
tion, saline was administered to the left eye of all 12 animals 
without special treatments and used as the control group (12 
eyes). Among 12 right eyes, in four eyes cases, a 5 mg/mL 
bevacizumab eye drop was administered twice a day for two 
weeks, and in the other four eyes cases, a 10 mg/mL bev-
acizumab eye drop was administered twice a day for two 
weeks. The remaining four eyes were treated with the sub-
conjunctival injection of 1.25 mg (0.01 mL) bevacizumab 
once, and afterward, no other treatments were administered.
The analysis of the neovascularization area 
The picture of the cornea of each experiment group was 
taken one week and two weeks after treatment with a camera 
(Contax D-7, Stutgart, Germany) attached to a microscope 
(S21; Carl Zeiss, Jena, Germany) at 25 times magnification, 
and the neovascularization area was measured using 
Axiovision AC software (Carl Zeiss). Considering the area 
prior to treatment as one, the relative reduction level was cal-
culated and analyzed. 
Histological examination and the calculation of VEGF 
concentration 
 Two weeks after treatment, both eyes of 12 animals were 
extracted and the neovascularization area was cut into 
halves. The area with neovascularization was prepared as 
sections, and a histological test was performed. Of corneal 
sections obtained from each eye, one half was fixed in 10% 
neutral formalin, and after a dehydration process, embedded 
in paraffin. Sections were then prepared, stained with hema-
toxylin & eosin, and examined under a biomicroscope 
(BX-50; Olympus, Tokyo, Japan). From the remaining cor-
neal sections, the area with neovasculatures was measured 
accurately, and then immediately stored in a -80℃ freezer. 
For these tissues, 1 mm phenylmethylsulfonylfloride was 
added to phosphate buffered saline, and then homogenized as 
200 μL/g volume. Afterward, the samples were centrifuged 
at 1,000 g, at 4℃ for ten minutes, and only the supernatant 
was used. The concentration of VEGF in tissues was meas-
ured by luminometer using the human VEGF immunoassay 
kit (R&D System, Minneapolis, MN, USA).
Statistical analysis 
The statistical analysis on the change of vascularization 
area and VEGF concentration was performed by Mann-Whitney 
U-test and a p-value less than 0.05 was considered to be 
significant.
Results
Analysis of the area of corneal neovascularization
In all rabbits, sufficient neovasculature was formed on day 
seven after corneal suture, while infection, as well as other 
specific findings, were not detected. Images of the corneal 
neovascularization area enlarged 25 times were taken using a 
microscope, and the images prior to surgery, the first week, 
and the second week were compared and analyzed (Fig. 1).
The area of neovascularization of each group was analyzed 
and compared, and the result revealed that the groups ad-
ministered 5 mg/mL bevacizumab, 10 mg/mL bevacizumab, 
and subconjunctival injection of 1.25 mg bevacizumab 
showed greater reduction of neovascularization area than the 
control group (Fig. 2).
Comparing the difference between the groups ad-
ministered 5 mg/mL bevacizumab eye drop and 10 mg/mL 
eye drop, the p-value (Mann-Whitney U-test) of week 1 was 
0.248, of week 2 was 0.083; a significant difference was not HO Jeong, et al. Bevacizumab and Corneal Neovascularization
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Fig. 3. Light microscopic examination of cornea stained with hematoxylin-eosin. (A) Some new vessels were seen in the stroma of the 
control group. (B) Some ghost vessels were seen and new vessels were almost regressed in that of groups treated with topical 5 mg/mL 
bevacizumab. Markedly regressed new vessels were also observed in that of the group treated with topical 10 mg/mL bevacizumab (C) 
and subconjunctival bevacizumab 1.25 mg injection (D). There were no pathologic changes in the stroma, epithelium, and endothelium 
of all groups. 
shown. Comparing the groups administered bevacizumab 
eye drop and treated by subconjunctival injection, a significant 
difference was not detected at the first week. However, the 
group treated with 10 mg/mL bevacizumab eye drop showed 
a more significant reduction of neovascularization area than 
the group treated by subconjunctival injection at the second 
week (Fig. 2).
The result of histological examination under light microscope 
The result of corneal section examination two weeks after 
treatment revealed that a greater neovascularization reduc-
tion within the corneal stroma than the control group was 
shown in the three treated groups. However, among the treat-
ed groups, a great difference in the number and area of neo-
vasculatures was difficult to detect. Over the study period, 
significant injury in the corneal epithelium, stroma, and en-
dothelium, that is, superficial punctate erosion, change of 
corneal thickness, conjunctival injection or any other type of 
corneal complication were not observed in all eyes (Fig. 3). 
Measure of vascular endothelial growth factor concentration 
The concentration of VEGF in each corneal section was 
compared, and the result showed that the control group con-
tained 1,284.33±223.01 pg/mL, while the groups treated 
with 5 mg/mL bevacizumab eye drop, 10 mg/mL eye drop, and 
subconjunctival injection were shown to be 998.33±130.93 
pg/mL, 942.00±32.86 pg/mL, and 968.24±83.34 pg/mL, 
respectively. The treated group showed a reduction of sig-
nificant concentrations in comparison with the control group 
(p<0.05), but a significant difference of concentrations was 
not detected among the three treated groups (p>0.05) (Fig. 4). 
Discussion
To maintain the transparency of the cornea, it is very im-
portant to maintain avascularity, and for this, the appropriate 
homeostasis of vascular inhibitor factors and vascular 
growth factors should be maintained. When the balance of 
angiogenic factors such as fibroblast growth factor (FGF) 
and VEGF, and angiogenic suppressors such as angiostatin, Korean J Ophthalmol Vol.24, No.4, 2010
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Fig. 4. Mean concentration of vascular endothelial growth factor 
(VEGF) (pg/mL) in the cornea after two weeks treatment. A p-value 
was estimated by comparing each group with the control group 
(Mann-Whitney U-test). The treated group showed a reduction of 
significant concentrations in comparison with the control group.
endostatin, and pigment epithelium derived factor (PEDF) 
are disrupted by diseases, neovascularization develops 
[1,21].
For the treatment of corneal neovasculature, various drug 
therapies, laser photocoagulation, and surgical therapy have 
been attempted, but established therapeutic methods are not 
currently available. Previously, drug therapies including, steroid 
[6,8], non-steroid anti-inflammatory agents [3], cyclosporin 
A [22], thalidomide [3], prolactine [3], methotrexate [7], and 
angiostatin [4], have been reported. Although steroid eye 
drop therapy has been used most widely for the treatment and 
prevention of corneal neovascularization presently, it may 
cause glaucoma, cataract, infection, and other complications. 
Hence, its long term use can pose complications [6,8]. 
Studies attempted to treat corneal neovasculature by the ap-
plication of angiogenesis suppressor factors such as angiostatin 
or PEDF, have been conducted, however, they eventually 
failed. Corneal laser photocoagulation using an argon laser 
may accompany recurrence of neovascularization, heat injury 
of adjacent tissues, and the consequent increase of inflammation 
[9]. As surgical therapy, limbal transplantation [23] or amniotic 
membrane transplantation [6] has been attempted, however, 
positive effects were not reported.  
 Recently, photodynamic treatment using verteporfin also 
has been used for the treatment of corneal neovascularization. 
Its short term effect has been reported to be very positive, but 
its long term effect has not been proven [10,11]. In addition, 
it has to be injected intravenously and repeated treatments 
are required, therefore its cost may become extremely high. 
Because of such diverse problems, verteporfin has been rare-
ly used in clinics to date [24,25].  
VEGF has been reported to play a very important role in nu-
merous ophthalmic diseases accompanying neovascularization. 
VEGF stimulates and accelerates the various processes of 
neovascularization (protein degradation, proliferation, mi-
gration of endothelial cells, and formation of capillary blood 
vessels). In addition, in recent studies, VEGF-A has shown 
involvement not only in neovascularization, but also lym-
phangiogenesis [26,27]. VEGF is not only involved in the 
regulation of neovascularization, it also has been proven in 
animal studies that if VEGF were suppressed at the level of 
mRNA or protein, corneal neovascularization was also de-
creased [2,14,27]. 
Bevacizumab is a recombinant monoclonal antibody and it 
inhibits the binding of VEGF-A to its receptor by binding to 
VEGF-A [28]. Recently, in the treatment of choroidal neo-
vascularization associated with age-related macular degener-
ation, positive results of the injection treatment of bev-
acizumab into the vitreous body have been reported [16-18].  
Moreover, the injection of bevacizumab within the vitreous 
body has been reported to be very effective on the degeneration 
of the neovasculature in the iris or the iridial corneal margin 
area [29]. The safety of the drug has been reported to be ex-
cellent, and its systemic use has been reported to increase hy-
pertension and thrombosis at a mild level in the treatment of 
colorectal cancer. However, its probability is very low, and it 
is thought that in cases of eye drop or subconjunctival in-
jection, the incidence would be substantially decreased 
[30,31]. Also in cases where bevacizumab is injected within 
the vitreous body, special systemic side effects have not yet 
been reported [32]. 
During the injection of bevacizumab within the vitreous 
body, 1-2 mg is injected, and considering the vitreous body 
volume (5.2 mL), the concentration corresponding to 0.2-0.4 
mg/mL [16-18]. Considering that the vitreous body is a 
closed space, it is thought that a concentration higher than 
this is required for the eye drop to be effective on corneal 
neovasculature. Therefore, in this study, neovascularization 
was induced in the cornea of house rabbits, 5 mg/mL or 10 
mg/mL bevacizumab eye drop was administered to the eye, 
and 1.25 mg was used for the injection within the vitreous 
body.
Our experiments showed that the results of the groups 
treated with eye drop and subconjunctival injection were sig-
nificant (p<0.05), but corneal neovasculature could not be 
completely removed. Considering the several causes of neo-
vasculature formation, administration of bevacizumab twice 
a day alone via eye drop may not be effective. It is possible 
that the administered drug is removed by tears, and thus it 
could not react with all VEGF receptors. In fact, in our ex-
periment, upon analysis of the VEGF concentration of corneal 
sections, the treatment group showed significantly lower val-
ues than the control group. Nevertheless, the VEGF concen-
tration of the control group was still maintained at a constant 
level (Fig. 4). In other words, even after treatment, a large 
number of VEGF still remained in tissues. However, even in 
cases of subconjunctival injection, the result was not sig-
nificantly different from eye drop treatments, and considering 
that the half-life of bevacizumab is less than 30 minutes, it 
appears that removal of the drug via tears may not be a great 
factor. In addition, the difference of the treatment according HO Jeong, et al. Bevacizumab and Corneal Neovascularization
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to eye drop concentrations was shown to be not significant 
(Fig. 2), therefore additional studies on this variable are also 
required. Moreover, our findings may be due to the presence 
of other cytokines (transforming growth factor a and b2; TGF 
a and b1, and FGF involved in corneal neovascularization in 
addition to VEGF) [21]. In the future, if drugs suppressing 
these cytokines were developed, a combination therapy may 
be considered. Third, the treatment period may also be 
considered. Actually, the eye drop treatment was terminated 
in two weeks, and the subconjunctival injection was termi-
nated after only one treatment. Nonetheless, at two weeks af-
ter treatment, the neovasculature area was definitely smaller 
than after one week, and at the second week, the outcome of 
eye drop treatment was significantly better than the subcon-
junctival treatment (p=0.043). To improve the treatment ef-
fectiveness, prolonging the duration of eye drop treatment or 
repeated subconjunctival treatments may be one option.          
Presently, the focus of bevacizumab application to the 
treatment of corneal neovascularization was the administration 
route and dose. Regarding the subjects, numerous studies 
have been performed recently.  Furthermore, Bock et al. [33]
 
have proven the fact that in experimental rat models, bev-
acizumab suppressed not only corneal neovascularization, but 
also neo-lymphangiogenesis, and both systemic administration 
and eye drop administration were reported to be effective. In 
addition, during the experiment processes, toxicity on the 
cornea was not detected. Manzano et al. [34]. have reported 
that for the treatment of the neovascularization in the rat cor-
nea, a 4 mg/mL bevacizumab eye drop was administered, 
and satisfactory results were obtained. Erdurmus and Totan 
[35] have reported that in human eyes, 2.5 mg bevacizumab 
(0.1 mL) was injected subconjunctivally to two eyes with the 
neovasculature, which proved effective within one week, and 
special systemic complications were not detected. Only in 
one eye case, the degeneration of large blood vessels was not 
noticeable, which shows the necessity of diverse clinical 
studies on the dose of bevacizumab, with or without repeated 
injections, or in combination with other therapies.   
In our study, regarding the effectiveness differences ac-
cording to the eye drop concentration, the effectiveness was 
shown to not vary by the analysis of the neovasculature area 
and VEGF concentration, which shows that both routes are 
effective. However, if a difference between the eye drop 
treatment and the subconjunctival injection treatment was 
detected at the second week of treatment, the repeated treat-
ment of the subconjunctival injection should be considered.
In addition to bevacizumab, ranibizumab (Lucentis; 
Genentech, San Francisco, CA, USA) [36], and pegaptanib 
sodium (Macugen; Eyetech Pharmaceuticals, New York, 
NY, USA) [37], are antibodies to VEGF developed recently. 
While these two drugs were already approved for the oph-
thalmic application, their shortcoming is excessively high 
cost. In the future, if the cost problem were solved, the use of 
these drugs for the treatment of corneal neovascularization 
should be also considered.   
Because bevacizumab suppresses the proliferation of 
blood vessel and lymphoid tissues, it is hypothesized that it 
may elevate the survival rate of grafts after corneal trans-
plantation, and it may be used for diverse ophthalmic diseases 
such as the treatment of herpes keratitis with neovascularization 
and the prevention of recurrence after the pterygium surgery. 
Based on our study, it is thought that bevacizumab would be 
used as a definite supplement therapy for the treatment of 
corneal neovascularization in the future, and clinical studies 
on the dose, administration route, administration duration, 
and frequency are required.
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